A Dose of Economics

US pharmaceutical prices are the highest in the world -- President Trump's Most Favoured Nation (MFN) policy is trying to change that. But what does MFN pricing mean in practice? And what are the global ripple effects on drug innovation and R&D? 

 
Grace Hampson is joined by Neil Grubert and Amanda Cole to talk about the biggest developments in U.S drug pricing policy – and what it means for the rest of the world.  

A Dose of Economics is Grace and the Office of Health Economics (OHE) team thinking out loud — debating the questions that matter most in healthcare policy, resource allocation, and health system decision-making, with the experts doing the work at the highest level. New episodes drop every Tuesday.  

If there’s a topic you’d like us to cover, feel free to share your ideas.

When demand for healthcare is growing but budgets are finite, the "how" and "why" of decision-making matters. 

In this first episode, host Grace Hampson, a Director at the Office of Health Economics (OHE), introduces the podcast, and sets out what you can expect this season. 

One question will run through every conversation: what can health economics bring to the most pressing problems in healthcare today? 

From cost-effectiveness thresholds and health technology assessment (HTA), to AI in health economics, rare diseases, drug pricing policy, antibiotics, and prevention, A Dose of Economics gets to the heart of the matter with expert guests closest to the work.